AnalyzeDirect Pritchard S, Glover M, Guthrie G, Brum J, Ramsey D, Kappler G, Thomas P, Stuart S, Hull D, Gowland P. Effectiveness of 0.05% oxymetazoline (Vicks Sinex Micromist(R)) nasal spray in the treatment of objective nasal congestion demonstrated to 12 h post-administration by magnetic resonance imaging. Pulm Pharmacol Ther. February 2014;27(1):121-126.
Publication Date
February 2014
How Analyze was Used
“All MRI data were analysed using a proprietary software package Analyze 9[.0]… .Each map was saved for future reference and used to calculate the regional volume measurements within Analyze 9[.0].”
Keywords
Administration, Intranasal
Adolescent
Adult
Female
Humans
Magnetic Resonance Imaging (MRI)
Male
Middle Aged
Nasal Decongestants/administration & dosage/therapeutic use
Nasal Obstruction/drug therapy/etiology
Nasal Sprays
Oxymetazoline/administration & dosage/therapeutic use
Reproducibility of Results
Severity of Illness Index
Time Factors
Young Adult
Long-lasting
Mri
Nasal turbinates
Oxymetazoline
Volume measurement
Author Affiliation(s)
Sir Peter Mansfield Magnetic Resonance Centre, School of Physics and Astronomy, The University of Nottingham, Nottingham, UK. (SP, PG)
Division of Therapeutics and Molecular Medicine, University of Nottingham, UK. (MG, CG)
Procter & Gamble, Whitehall Lane, Egham, Surrey, UK. (SS, DH)
Procter & Gamble, Mason, OH, US. (JB, DR, GK, PT)
ID# 1200
Tags: Adolescent, Adult, Female, Humans, Intranasal Administration, Magnetic Resonance Imaging (MRI), Male, Middle Aged, Nasal Decongestants/administration & dosage/therapeutic use, Nasal Obstruction/drug therapy/etiology, Nasal Sprays, Oxymetazoline/administration & dosage/therapeutic use, Reproducibility of Results, Severity of Illness Index, Time Factors, Young Adult